U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. The OCE Equity Program
  1. Oncology Center of Excellence

The OCE Equity Program

Generating Evidence for Diverse Populations in Oncology

Project Equity 2023

The OCE Equity Program is a public health initiative established by the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) to improve access to clinical trials of oncology medical products for populations that have been historically underrepresented in clinical research, such as racial and ethnic minorities, individuals who live in rural areas, sexual and gender minorities, and individuals with economic, linguistic, or cultural barriers to healthcare services. The OCE Equity Program seeks to advance equitable access to clinical trials for all patients with cancer through policy, research, and education.

Goals of The OCE Equity Program:

  • Develop and promote policies to ensure adequate enrollment of historically underrepresented and vulnerable subgroups in oncology clinical trials intended to support FDA approval to evaluate any differences that may exist across the population.
  • Engage and collaborate with internal and external stakeholders on research, policy, and educational initiatives to promote access to and advance equity in clinical trials.
  • Conduct and present analyses of data generated through clinical trials and other data sources to evaluate outcomes across subgroups.

OCE looks forward to further engaging with the community and other stakeholders to advance this effort. For inquiries regarding this program, please contact OCE-Equity@fda.hhs.gov.

Program Leads: Nicole Gormley, MD, Associate Director for Equity Advancement, OCE; and Tamy Kim, PharmD, Director for Regulatory Affairs and Policy, OCE

Program Manager: Jennifer Lee, PharmD, RAC; Senior Health Scientist, OCE

Additional Resources

Back to Top